Search
Returning search results with filters:
Remove filter for
Audience: Healthcare
Remove filter for
Category: Biologic or vaccine
Remove filter for
Issue: Health products
Remove filter for
Type: Alert
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 31 - 44 of 44 items.
Authorization of Bamlanivimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
AlertHealth professional risk communication | 2020-12-18
Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies
AlertPublic advisory | 2020-12-12
Authorization of Pfizer-BioNTech COVID-19 Vaccine with English-only Carton and Vial Labels
AlertHealth professional risk communication | 2020-12-12
Clinical management support: Known interference between Hemlibra® (emicizumab injection) and lab assays used to diagnose coagulopathy / DIC caused by COVID-19 infection
AlertHealth professional risk communication | 2020-04-17
Health Canada clarifies position on Platelet Rich Plasma treatments
AlertInformation update | 2019-07-26
PrBENLYSTA (belimumab) - Increased Risk of Serious Depression, Suicidal Ideation or Behaviour, or Self-Injury
AlertHealth professional risk communication | 2019-04-04
DARZALEX (daratumumab) and Hepatitis B Virus Reactivation
AlertHealth professional risk communication | 2019-03-25
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Myositis
AlertHealth professional risk communication | 2019-03-13
LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
AlertHealth professional risk communication | 2019-01-30
XOFIGO® (radium Ra 223 dichloride) - Increased Incidence of Fractures and Trend for Increased Deaths with XOFIGO used in combination with abiraterone and prednisone/prednisolone
AlertHealth professional risk communication | 2018-11-08
TECENTRIQ® (atezolizumab) - Risk of Immune-Related Nephritis
AlertHealth professional risk communication | 2018-09-18
Several GlaxoSmithKline Inc. vaccines: Potential Risk of Underdosing
AlertHealth professional risk communication | 2018-05-01
ZINBRYTA (daclizumab beta) - Voluntary Withdrawal in Canada due to Risk of Encephalitis
AlertHealth professional risk communication | 2018-03-16
Shortage of Erwinase for Injection and Replacement with UK Labelled Stock
AlertHealth professional risk communication | 2018-02-27